2017
DOI: 10.1159/000485955
|View full text |Cite
|
Sign up to set email alerts
|

Strengthening Gastric Cancer Therapy by Trastuzumab-Conjugated Nanoparticles with Simultaneous Encapsulation of Anti-MiR-21 and 5-Fluorouridine

Abstract: Background/Aims: MicroRNA-21 is an oncogenic miR (oncomiR) frequently elevated in gastric cancer (GC). Overexpression of miR-21 decreases the sensitivity of GC cells to 5-fluorouridine (5-Fu) and trastuzumab, a humanized monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2). Receptor-mediated endocytosis plays a crucial role in the delivery of biotherapeutics including anti-miRNA oligonucleotides (AMOs). This study is a continuation of earlier findings involving poly(ε-caprolactone) (PC… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
16
0

Year Published

2018
2018
2023
2023

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 37 publications
(16 citation statements)
references
References 42 publications
0
16
0
Order By: Relevance
“…89 Hu's team and Wu's team each introduced PCL-PEG nanoparticles coated with trastuzumab (HER-PEG-PCL NPs) to control the delivery of the inhibitor of miRNA. 12,90 These studies, respectively, verified the inhibitory function of miR-34a, miR-21, miR-542-3p, and miR-200c on GC in vitro or in vivo. Importantly, these strategies involve the use of synthetic nanoparticles and compounds to attempt to solve the problem of improving microRNAs-targeted transport to tumors so as to promote the clinical application of microRNA-based targeted therapies.…”
Section: Synthetic Nanoparticles and Compoundsmentioning
confidence: 74%
See 1 more Smart Citation
“…89 Hu's team and Wu's team each introduced PCL-PEG nanoparticles coated with trastuzumab (HER-PEG-PCL NPs) to control the delivery of the inhibitor of miRNA. 12,90 These studies, respectively, verified the inhibitory function of miR-34a, miR-21, miR-542-3p, and miR-200c on GC in vitro or in vivo. Importantly, these strategies involve the use of synthetic nanoparticles and compounds to attempt to solve the problem of improving microRNAs-targeted transport to tumors so as to promote the clinical application of microRNA-based targeted therapies.…”
Section: Synthetic Nanoparticles and Compoundsmentioning
confidence: 74%
“…10 In addition, synthetic carriers have been used to deliver the confirmed anti-tumor miRNAs to the precise tumor site so as to directly inhibit GC, such as "PPP", which was constructed by modifying phenylboronic acid onto the surface of a polyamidoamine dendrimer and poly (ethylene glycol)-poly(ε-caprolactone) copolymers (PEG-PCL) nanoparticles coated with trastuzumab. 11,12 Indeed, these studies have led to a major advance in the clinical application of miRNAs. Moreover, these findings suggested that in addition to their function as biomarkers, miRNAs can also play roles in the treatment of tumors.…”
Section: Introductionmentioning
confidence: 99%
“…It is also demonstrated that ERBB3 is involved in resistance to EGFR or ERBB2 targeted therapy for cancer [27]. Furthermore, the study of nanoparticles targeting ERBB2 and microRNA21 suggests the importance of ERBB signaling in cancer [28]. These insights indicate the significance of regulation of ERBB2 and ERBB3 signaling in cancer.…”
Section: Discussionmentioning
confidence: 94%
“…Furthermore, it also can prevent uracil and orotic acid uptake into RNA to inhibit the effects of RNA, and thus interferes with the biosynthesis of RNA, DNA, and proteins [3,4]. 5-FU has a broad anticancer spectrum and obvious curative effects, and either alone or in combination with other anticancer drugs, it plays an important role in the treatment of most common tumors of the digestive tract such as gastric cancer [5], colorectal carcinoma [6], and hepatoma [7]. To date, it cannot be replaced by other drugs, especially for the treatment of gastrointestinal tumors.…”
Section: Introductionmentioning
confidence: 99%